Patents Examined by Lisa B. Arthur
  • Patent number: 6221596
    Abstract: A method for isolating a rare cell type from a sample including a mixed population of cells is provided, which employs (a) an image processor being designed for morphologically differentiating the rare cell type from the mixed population of cells; (b) a magnifying device communicating with the image processor for providing a magnified image of at least a portion of the sample to the image processor; and (c) a micromanipulator for retrieving the rare cell type out of the mixed population of cells according to information provided by the image processor.
    Type: Grant
    Filed: May 17, 1999
    Date of Patent: April 24, 2001
    Assignee: Motobit Ltd.
    Inventors: Adi Yemini, Ziva Yemini
  • Patent number: 6218151
    Abstract: The extension of primers capable of hybridizing to the nucleic acid of interest results in a process for generating single-stranded polynucleotides. The process includes contacting the nucleic acid of interest under conditions allowing extension of the primers with a first primer and a second primer capable of hybridizing to a first region and a second region, respectively, of the nucleic acid, wherein the second region overlaps with the first region.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: April 17, 2001
    Assignee: Bio Merieux
    Inventors: Philippe Cleuziat, Francoise Guillou-Bonnici, Francois Mallet, Pierre Levasseur
  • Patent number: 6218104
    Abstract: High risk carcinogenic human types 16, 18 and 33 are distinguished from low risk human papillomavirus types 6 and 11 in a sample of human cervical tissue. A selected characteristic portion of the E6 region of the virus defined by specific oligonucleotide primers is amplified using a polymerase chain reaction. The presence or absence of the characteristic portion of the E6 region is detected by gel electrophoresis or using a labeled oligonucleotide probe.
    Type: Grant
    Filed: December 30, 1997
    Date of Patent: April 17, 2001
    Assignee: Biosearch International Pty. Ltd.
    Inventors: Brian James Morris, Brian Nightingale
  • Patent number: 6218109
    Abstract: The present invention relates to the isolation of gene sequences encoding mammalian cell cycle checkpoints, as well as the expression of the encoded proteins using recombinant DNA technology. The expressed proteins are used to generate specific antibodies and to inhibit the growth of cells. The human checkpoint gene sequences are used as a probe for a portion of the chromosome associated with tumors and other malignancies, as well as growth and/or development deficiencies.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: April 17, 2001
    Assignee: Baylor College of Medicine
    Inventors: Stephen J. Elledge, Yolanda Sanchez
  • Patent number: 6218110
    Abstract: A synthetic oligonucleotide which is complementary to a nucleotide sequence of a gene selected from the group consisting of the Shiga toxin gene of Shigella species, the ipaH gene of Shigella species and EIEC, the invE gene of Shigella species and EIEC, the araC gene of Salmonella species, the Verocytotoxin-1 gene of EHEC or VTEC, the Verocytotoxin-2 gene of EHEC or VTEC, the toxic shock syndrome toxin-1 gene of Staphylococcus aureus, the ctx gene of Vibrio cholerae, and the enterotoxin gene of Clostridium perfringens; a method for detecting a bacterial strain by amplifying a region of the above gene by PCR using the above oligonucleotides as primers and detecting the amplified region; and a kit for the detection of the bacterial strain.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: April 17, 2001
    Assignee: Shimadzu Corporation
    Inventors: Tomoko Nakayama, Jun Tada, Shigeru Fukushima, Tetsuo Ohashi
  • Patent number: 6200749
    Abstract: A purified and isolated gene, designated ATM, is described mutations of which cause ataxia-telangiectasia and its genomic organization.
    Type: Grant
    Filed: May 3, 1996
    Date of Patent: March 13, 2001
    Assignee: Ramot-University Authority for Applied Research and Industrial Development Ltd.
    Inventor: Yosef Shiloh
  • Patent number: 6190860
    Abstract: The present invention provides recombinant polypeptides derived from CMV glycoprotein gB and truncated fragments thereof which contain at least one epitope which is immunologically identifiable with one encoded by the CMV genome. The complete characterization of the gB protein, including the identity of glycoprotein gp55, permits the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. This invention provides recombinant polypeptides and recombinant polynucleotides encoding these polypeptides wherein a neutralizing epitope of gB is localized within gp55.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: February 20, 2001
    Assignee: Chiron Corporation
    Inventors: Richard R. Spaete, Carol A. Pachl
  • Patent number: 6183964
    Abstract: Intragenic suppressor mutations of common p53 mutations are able to function in cis and/or trans. These mutations are useful for identifying small molecule drugs which function in a similar fashion. In addition, the mutations themselves may be useful therapeutically, especially if they function in trans. Methods for rapidly obtaining this type of mutant employ a yeast selection system. Cells having both the negative mutation and intragenic suppressor are useful for studying the interactions of the two, in particular in determining the structure of the homotetramers and heterotetramers.
    Type: Grant
    Filed: November 2, 1998
    Date of Patent: February 6, 2001
    Assignee: The Johns Hopkins University
    Inventors: Jef D. Boeke, Rainer K. Brachmann
  • Patent number: 6183953
    Abstract: Methods for altering a selected chromosomal locus in P. methanolica cells and cells comprising such altered loci are disclosed. A linear DNA construct comprising (i) a segment comprising a portion of the target locus in which at least one nucleotide pair is altered and (ii) a selectable marker that complements adenine auxotrophy is introduced into cells auxotrophic for adenine. The cells are cultured under selective conditions, and cells in which the linear DNA construct has been chromosomally integrated by homologous recombination are identified. The cells are then cultured under conditions whereby cells auxotrophic for adenine can be identified, and a subset of such cells in which the altered locus has been chromosomally integrated are identified.
    Type: Grant
    Filed: December 30, 1997
    Date of Patent: February 6, 2001
    Assignee: ZymoGenetics, Inc.
    Inventor: Christopher K. Raymond
  • Patent number: 6177252
    Abstract: The T/C(67) AGT gene variant and the association of the molecular variant C(67) with predisposition of an individual to hypertension are disclosed. The determination of this association enables the screening of persons to identify the severity of hypertension or the severity of the risk of a predisposition to high blood pressure.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: January 23, 2001
    Assignee: University of Utah Research Foundation
    Inventors: Andreas Rohrwasser, Jean-Marc Lalouel
  • Patent number: 6165714
    Abstract: The invention provides devices and methods for use in detecting nucleic acid analytes in samples. The devices each include a solid support to which is bound a two-dimensional distribution or field of nucleic acid probes that each bind to a nucleic acid analyte, which is detected by use of amplification methods.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: December 26, 2000
    Assignee: Vysis, Inc.
    Inventors: David J. Lane, Michael P. Farrell
  • Patent number: 6150096
    Abstract: The present invention relates to an arbitrarily primed PCR-based method to identify genetic marker associated with a pathology, which comprises the steps of: a) collecting heterogeneous nucleic acid samples from diseased and healthy tissues; b) determining quantities of the nucleic acid pools by specific amplification of a fragment of glyceraldehyde-phosphate dehydrogenase (GAPDH) mRNA; c) amplifying nucleic acid pools of step b) using non-specific sense and antisense primers to obtain clear patterns of nucleic acid sequences; and d) subjecting amplified nucleic acid sequences to gel electrophoresis to obtain fingerprints of both diseased and healthy, wherein bands predominantly associated with diseased tissues are markers for the pathology. The present invention also relates to a RNA expression marker for the diagnosis of Crohn's disease, which comprises a 3.1 kb RNA sequence, and uses thereof.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: November 21, 2000
    Assignee: Universite de Sherbrooke
    Inventors: Jean-Pierre Perreault, Daniel LaFontaine, Stephane Mercure
  • Patent number: 6146855
    Abstract: Oligonucleotide molecules and methods are disclosed for the detection of viable oocysts or other cells of the protozoa species, Cyrptosporidium parvum. Preferred oligonucleotide molecules are selected from the group comprising oligonucleotides having one or more of the following sequences: (a) ACA ATT ATT, (b) CTT TTT GGT, (c) ATT TTA TAT AAA ATA TTT TGA TGA A, (d) TTT TTT TTT TTA GTA T, (e) TAT ATT TTT TAT CTG, (f) CTT TAC TTA CAT GGA TAA CCG, or comprising a part of the sequences (a) to (f) above so as to allow specific hybridization to unique 18S rRNA sequences of C. parvum.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: November 14, 2000
    Assignees: Macquarie Research, Ltd., Australian Water Technologies Pty. Ltd.
    Inventors: Keith Leslie Williams, Graham Vesey, Duncan Veal, Nicholas John Ashbolt, Matthias Dorsch
  • Patent number: 6143500
    Abstract: The present invention is drawn to nucleic acid fragments specific to Xanthomonas campestris pathogenic to plants belonging to the family Gramineae, as well as methods for detecting the pathogenic Xanthomonas campestris using the same. The nucleic acid fragment of the invention has a nucleotide sequence which is at least 15 consecutive nucleotides of the nucleotide sequence shown in SEQ ID NO:1 or in the complementary chain thereof, or has no less than 15 nucleotides and hybridizes with the nucleic acid having the sequence shown in SEQ ID NO:1 or with the complementary chain thereof under stringent conditions.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: November 7, 2000
    Assignee: Japan Tobacco, Inc.
    Inventor: Tomoki Nishino
  • Patent number: 6140496
    Abstract: The disclosure describes building blocks for preparing oligonucleotides carrying non-standard nucleobases that can pair with complementary non-standard nucleobases so as to fit the Watson-Crick geometry, in that the resulting base pair joins a monocyclic six membered ring pairing with a fused bicyclic heterocyclic ring system composed of a five member ring fused with a six member ring, with the orientation of the heterocycles with respect to each other and with respect to the backbone chain analogous to that found in DNA and RNA, but with a pattern of hydrogen bonds holding the base pair together different from that found in the AT and GC base pairs (a "non-standard base pair").
    Type: Grant
    Filed: December 31, 1996
    Date of Patent: October 31, 2000
    Inventor: Steven Albert Benner
  • Patent number: 6136533
    Abstract: A method for detecting a target nucleic acid molecule is provided, comprising the steps of (a) reacting a mixture comprising (i) a target nucleic acid molecule; (ii) a single-stranded nucleic acid probe containing a scissile linkage; (iii) an enzyme capable of cleaving the probe portion of a double-stranded target-probe complex at the scissile linkage; and (iv) ribosomal protein and/or spermine, under conditions and for a time sufficient to allow the target nucleic acid and probe to hybridize to each other and form a double-stranded target-probe complex, followed by cleavage of the probe and cycling of the target to a new uncleaved probe, such that one or more portions of the cleaved nucleic acid probe are released from the target-probe complex; and (b) determining whether cleaved portions of the nucleic acid probe are produced, and thereby detecting the presence of the target nucleic acid.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: October 24, 2000
    Assignee: ID Biomedical
    Inventors: Faouzi Bekkaoui, Zora D. Modrusan, Isabelle A. Piche, Peter D. Duck, Lynn P. Cloney, Alfred C. K. Wong
  • Patent number: 6117636
    Abstract: A method for detecting Byssochlamys nivea, Neosartorya fischeri and Zygossaccharomyces bailii micro-organisms by amplifying the genomic DNA of the targeted micro-organisms using as a primer a sequence contained on the internal transcript spacers (ITS) of the ribosomal unit, namely, for Byssochlamys nivea, on ITS1 corresponding to SEQ ID 1 and on ITS2 corresponding to SEQ ID 2; for Neosartorya fischeri, on ITS1 corresponding to SEQ ID 3, and on ITS2 corresponding to SEQ ID 4; and for Zygosaccharomyes bailii, on ITS1 corresponding to SEQ ID 5 and on ITS2 corresponding to SEQ ID 6.
    Type: Grant
    Filed: March 9, 1998
    Date of Patent: September 12, 2000
    Assignee: Ultra Propre Nutrition Industrie Recherche
    Inventors: Emmanuelle Chrzavzez nee Taddei, Robert Aufrere
  • Patent number: 6114150
    Abstract: Methods and compositions are provided to obtain uniform amplification of nucleic acid templates having varied G+C contents by adding betaine and DMSO to the reaction mixture.
    Type: Grant
    Filed: December 2, 1996
    Date of Patent: September 5, 2000
    Assignee: Yale University
    Inventors: Sherman M. Weissman, Namadev Baskaran
  • Patent number: 6110673
    Abstract: The present invention provides new probes for the detection of chromosomal alterations associated with cancer, particularly ovarian cancer. The probes bind selectively with target nucleic acid sequences at 3q26 and at 19q13.1-19q13.2.
    Type: Grant
    Filed: April 5, 1997
    Date of Patent: August 29, 2000
    Assignee: The Regents of the University of California
    Inventors: Laleh Shayesteh, Joe W. Gray
  • Patent number: 6100031
    Abstract: The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers (e.g., colon cancer) in mammals, e.g., humans. The invention is based on the discovery of genes that are differentially expressed in tumor cells relative to normal cells. The genes identified can be used diagnostically or as targets for therapy, and can be used to identify compounds useful in the diagnosis, prevention, and therapy of tumors and cancers.
    Type: Grant
    Filed: March 5, 1998
    Date of Patent: August 8, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Andrew W. Shyjan